Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors.

ABSTRACT:

Purpose

In this first-in-human dose escalation study, the safety and efficacy of IO-108, a fully human monoclonal antibody targeting leukocyte immunoglobulin-like receptor B2 (LILRB2), was investigated in patients with advanced solid tumors as monotherapy and in combination with pembrolizumab, an anti-programmed cell death protein 1 (PD-1) antibody.

Methods

The study included patients with histologically or cytologically confirmed advanced and relapsed solid tumors, with measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST) V.1.1. Patients were treated with escalating doses of IO-108 every 3 weeks (Q3W) as monotherapy and in combination with pembrolizumab. Safety and tolerability were the primary objectives. Secondary and exploratory objectives included

SUBMITTER: Taylor MH 

PROVIDER: S-EPMC11580248 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature